LON:CLIN Clinigen Group (CLIN) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Clinigen Group Stock (LON:CLIN) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Clinigen Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range 925▼ 92552-Week Range N/AVolume539,375 shsAverage Volume1.83 million shsMarket Capitalization£1.23 billionP/E Ratio64.69Dividend Yield0.82%Price TargetN/AConsensus RatingN/A Company OverviewClinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More… Receive CLIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter. Email Address CLIN Stock News HeadlinesEvotec Shares Jump After Triton Acquires StakeNovember 11, 2024 | marketwatch.comTriton Weighs Takeover Deal for Drug Developer EvotecNovember 11, 2024 | finance.yahoo.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 25, 2024 | Brownstone Research (Ad)Photocure establishes Named Patient Program to provide access to Hexvix in South AfricaSeptember 27, 2024 | finance.yahoo.comIovance Therapeutics: Historic Product, Tough Commercial OutlookSeptember 6, 2024 | seekingalpha.comCompounding Pharmacy Market Size to Increase USD 29.85 Billion by 2033April 17, 2024 | finance.yahoo.comElliott Alumnus De La Riviere Joins Tech Entrepreneur’s FundMarch 13, 2024 | bloomberg.comReal World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets.February 18, 2024 | finanznachrichten.deSee More Headlines CLIN Stock Analysis - Frequently Asked Questions How were Clinigen Group's earnings last quarter? Clinigen Group plc (LON:CLIN) posted its earnings results on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $63.50 by $2.10. How do I buy shares of Clinigen Group? Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Albemarle (ALB), Advanced Accelerator Applications (AAAP), First Hawaiian (FHB), General Electric (GE) and Landec (LNDC). Company Calendar Last Earnings9/17/2020Today12/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Delivery Sub-IndustryTrading Current SymbolLON:CLIN CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio64.69 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio90.77 Current Ratio1.89 Quick Ratio1.48 Sales & Book Value Annual Sales£565.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.48 Book ValueGBX 341.90 per share Price / BookN/AMiscellaneous Outstanding Shares133,367,000Free FloatN/AMarket Cap£1.23 billion OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (LON:CLIN) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinigen Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinigen Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.